Hyloris Lays Out Ambitious Plans For US
Value Added Medicines Specialist Reveals How It Will Use IPO Proceeds
Fresh from a successful IPO, Belgian value-added medicines specialist Hyloris Pharmaceuticals has the financial firepower it needs to pursue ambitious expansion plans that include building out a US commercial infrastructure, CEO Stijn Van Rompay tells Generics Bulletin in an exclusive interview.
